Immune recovery after autologous or rhG-CSF primed PBSC transplantation.
We performed a prospective study in 17 consecutive patients following Autologous bone marrow (BM) or rhG-CSF primed peripheral blood item cell (PBSC) transplantation, with the objective of comparing immune recovery between both procedures and to evaluate results in rhG-CSF mobilized peripheral blood stem cell transplantation (PBSCT). Kinetics of immune reconstitution showed differences, with a faster recovery of CD3+ and CD8+ T cells, and a more rapid and sustained recovery of CD8+/-/CD56+ natural killer (NK) cells in the PBCSCT group. Autologous bone marrow transplantation (ABMT) was associated with a improved reconstitution of the CD19+/CD5+/-subpopulation. Moreover, rhG-CSF mobilized PBSCT generated a greater recovery of CD8+/-/CD56+ cells than previous data concerning transplantation with peripheral blood (PB) progenitors collected after myelosuppressive chemotherapy or myelosuppressive therapy plus rhG-CSF. Our results show differences in the rate and pattern of B and T lymphocytes reconstitution after ABMT and PBSCT. Additionally, we state an enhancement of CD56+ cells in patients undergoing PBSCT mobilized solely using rhG-CSF.
Rosillo
M C
MC
Unit of Hematology and Hemotherapy, School of Medicine, Hospital General Universitario, Murcia, Spain.
Ortuño
F
F
Moraleda
J M
JM
Lozano
M L
ML
Heras
I
I
De Arriba
F
F
Vicente
V
V
D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D016026:Bone Marrow Transplantation / Q000276:immunology*; D001943:Breast Neoplasms / Q000276:immunology / Q000628:therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology*; D007938:Leukemia / Q000276:immunology / Q000628:therapy; D008223:Lymphoma / Q000276:immunology / Q000628:therapy; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology / Q000628:therapy; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000627:therapeutic use; D013234:Stem Cells / Q000187:drug effects; D013601:T-Lymphocytes / Q000276:immunology*; D014182:Transplantation, Autologous / Q000276:immunology; D008258:Waldenstrom Macroglobulinemia / Q000276:immunology / Q000628:therapy
D015703:Antigens, CD; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor